Published in Blood on November 24, 2010
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol (2014) 0.88
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators Inflamm (2015) 0.86
Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2012) 0.86
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood (2014) 0.81
The treatment of essential thromobocytosis revisited. Blood (2011) 0.81
Does thrombocyte size give us an idea about thrombocytosis etiology? ScientificWorldJournal (2012) 0.77
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica (2016) 0.75
Equivalence of BCSH and WHO diagnostic criteria for ET. Leukemia (2016) 0.75
Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience. Contemp Oncol (Pozn) (2015) 0.75
Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review. J Adv Res (2017) 0.75
Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report. Stem Cell Investig (2016) 0.75
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med (2010) 5.06
Non-inferiority trials are unethical because they disregard patients' interests. Lancet (2007) 4.72
Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
The myeloproliferative disorders. N Engl J Med (2006) 4.30
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer (2007) 3.89
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet (2007) 3.53
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 2.71
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood (2007) 2.44
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc (2006) 2.38
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia (2008) 2.35
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med (2008) 2.31
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood (2006) 2.08
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
Long-term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 1.81
Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med (1999) 1.79
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia (2007) 1.67
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med (1981) 1.52
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet (1978) 1.52
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood (2009) 1.48
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood (2008) 1.44
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia (2008) 1.43
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol (1990) 1.42
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol (2007) 1.42
Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol (2008) 1.40
Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med (1994) 1.39
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood (2008) 1.33
Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood (2000) 1.29
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood (2010) 1.29
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol (1999) 1.29
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica (2008) 1.27
A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc (2001) 1.27
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res (2009) 1.17
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia (2006) 1.16
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol (2009) 1.16
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol (2002) 1.14
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood (2007) 1.13
Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia (1999) 1.10
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol (2000) 1.07
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood (2007) 1.07
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol (2004) 1.06
Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol (2003) 1.06
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost (2006) 1.05
Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol (1998) 1.05
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res (2008) 1.03
K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis. PLoS One (2008) 1.01
Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utility. Cancer (2005) 0.97
Clinical course of essential thrombocythemia in 147 cases. Cancer (1990) 0.96
Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia (1999) 0.96
Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program (2005) 0.96
Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Hematol (2009) 0.93
Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program (2009) 0.93
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol (2001) 0.90
JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol (2009) 0.87
NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol (2007) 0.85
Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol (2007) 0.84
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol (2003) 0.84
Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia (2007) 0.84
Where do we go now with low molecular weight heparin use in obstetric care? J Thromb Haemost (2008) 0.81
The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol (1997) 0.81
A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol (2001) 0.80
Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. Haematologica (2010) 0.79
Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med (1995) 0.79
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia (2004) 0.79
Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin Haematol (1998) 0.78
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma (1996) 0.78
An inconvenient truth. Blood (2010) 0.77
Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol (2004) 0.77
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
The cancer genome. Nature (2009) 23.13
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
The myeloproliferative disorders. N Engl J Med (2006) 4.30
Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ (2008) 4.04
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Deciphering signatures of mutational processes operative in human cancer. Cell Rep (2013) 3.61
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 2.98
Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) (2011) 2.84
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Transcriptional regulation of the stem cell leukemia gene (SCL)--comparative analysis of five vertebrate SCL loci. Genome Res (2002) 2.77
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife (2013) 2.67
Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg (2009) 2.57
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Criteria for inference of chromothripsis in cancer genomes. Cell (2013) 2.51
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J (2002) 2.40
Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell (2012) 2.37
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood (2004) 2.30
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell (2011) 2.30
Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U S A (2007) 2.15
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A (2002) 2.08
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood (2006) 2.08
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2005) 1.92
Estimation of rearrangement phylogeny for cancer genomes. Genome Res (2011) 1.91
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood (2005) 1.91
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica (2007) 1.83
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Analysis of multiple genomic sequence alignments: a web resource, online tools, and lessons learned from analysis of mammalian SCL loci. Genome Res (2004) 1.80
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Single-cell paired-end genome sequencing reveals structural variation per cell cycle. Nucleic Acids Res (2013) 1.77
DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol (2007) 1.66
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood (2008) 1.59
Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest (2013) 1.58
In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood (2004) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood (2003) 1.54
Janus kinase deregulation in leukemia and lymphoma. Immunity (2012) 1.52
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Investigation of an incidental finding of eosinophilia. BMJ (2011) 1.46
Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass. J Cardiothorac Vasc Anesth (2004) 1.46
Hematologic features of hepatosplenic T-cell lymphoma. Am J Clin Pathol (2012) 1.46
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet (2013) 1.45
Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development. Hum Mol Genet (2005) 1.43
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol (2007) 1.42
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol (2012) 1.41